D. E. Shaw & Co., Inc. Mirum Pharmaceuticals, Inc. Transaction History

D. E. Shaw & Co., Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$27.14 - $34.93 $31,102 - $40,029	-1,146 Reduced 4.91%	22,178 $654,000
Q3 2023 Nov 14, 2023	BUY	$24.63 - $32.85 $574,470 - $766,193	23,324 New	23,324 $737,000
Q3 2022 Nov 14, 2022	BUY	$19.98 - $29.44 $225,953 - $332,936	11,309 Added 45.53%	36,145 $759,000
Q2 2022 Aug 15, 2022	BUY	$18.42 - $27.5 $457,479 - $682,990	24,836 New	24,836 $483,000
Q3 2020 Nov 16, 2020	SELL	$18.4 - $26.59 $194,690 - $281,348	-10,581 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$11.51 - $20.97 $121,787 - $221,883	10,581 New	10,581 $206,000

190

54M

177K

167K

Ticker MIRM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,751,700
Market Cap $1.64B
Description
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the trea...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.